Cookies Policy
X

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

Phage C31 integrase-mediated site-specific integration for gene therapy

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

This Article is currently unavailable for purchase.
Add to Favorites
You must be logged in to use this functionality

For most genetic disorders, long-term correction is necessary. Integration of a therapeutic gene into a patient's genome is an obvious route to achieving such permanent correction. Several technologies have been applied to the goal of achieving integration, including viruses and transposases. While these techniques are effective at some level, they each have drawbacks that can be improved upon. A novel integration system based on a phage integrase can address some of the previous limitations. The integrase from the Streptomyces bacteriophage C31 catalyzes site-specific, unidirectional integration into the genomes of higher eukaryotes. This integrase has the ability to recognize a limited number of native genomic sequences and integrate introduced plasmid DNA into them. These native sequences, termed pseudo att sites, resemble the wild-type phage attachment site enough to support integrase-mediated integration. Molecular evolution holds the promise of creating custom integrases that preferentially recombine at particular pseudo att sites. Furthermore, the system has no apparent size limit on carrying capacity. These features make the C31 integrase system extremely appealing for gene therapy applications. The system has been successfully employed in several model gene therapy studies to date. Here we review the development of this novel integration system and its current and potential applications to gene therapy.

10.1163/156855803322664600
/content/journals/10.1163/156855803322664600
dcterms_title,pub_keyword,dcterms_description,pub_author
10
5
Loading
Loading

Full text loading...

/content/journals/10.1163/156855803322664600
Loading

Data & Media loading...

http://brill.metastore.ingenta.com/content/journals/10.1163/156855803322664600
Loading

Article metrics loading...

/content/journals/10.1163/156855803322664600
2017-09-20

Sign-in

Can't access your account?
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation